Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
March 2013, Highlights
March 2013, Highlights
Breast Cancer Index Predicts Late Recurrences in Patients with ER-Positive Breast Cancer
By
Audrey Andrews
Prognostic Tests
,
Personalized Medicine
March 2013, Highlights
The Breast Cancer Index (BCI), a polymerase chain reaction–based assay, can predict late recurrences in estrogen receptor (ER)-positive patients, according to results from the translational arm of the Arimidex, Tamoxifen, Alone or in Combination (TransATAC) trial population.
Read Article
Eribulin Plus Trastuzumab an Effective Combination
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Eribulin mesylate (Halaven) is currently used in patients with metastatic breast cancer whose disease has progressed on other treatments, but the drug may be useful in earlier lines of therapy.
Read Article
Overall Survival Trend Seen with Eribulin versus Capecitabine
By
Audrey Andrews
March 2013, Highlights
A trend toward improved overall survival (OS) with eribulin mesylate (Halaven) was demonstrated in the global phase 3 clinical trial comparing this newer agent with capecitabine (Xeloda) in patients with previously treated metastatic breast cancer.
Read Article
HER2 Mutations May Become New Treatment Targets
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Some patients who test HER2 negative by conventional tests may still benefit from anti-HER2 agents. This is the conclusion of a study that examined HER2 mutations in detail which was presented by Ron Bose, MD, PhD, Assistant Professor, Oncology Division, Department of Medicine, Washington University School of Medicine in St Louis, MO.
Read Article
Results of Immunohistochemistry and In Situ Hybridization Reliable Indicators of HER2-Positive Status
By
Susan Reckling
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
The incidence of false-negative immunohistochemistry (IHC) is only 1% in patients with primary breast cancer, according to a prospective multicenter Canadian study presented at the meeting.
Read Article
One Year of Trastuzumab Remains the Standard of Care
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
For patients with HER2-positive early breast cancer, 1 year of treatment with trastuzumab (Herceptin) remains the standard of care, according to the HERA trial and a subanalysis of the PHARE study.
Read Article
HER2 Status Determined by Central Laboratory Testing May Be More Reliable than Routine Local Testing
By
Susan Reckling
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Determining HER2 status utilizing novel central laboratory testing techniques has been shown to be more reliable than routine local HER2 testing, such as immunohistochemistry or in situ hybridization.
Read Article
Hypofractionation Validated for Breast Radiotherapy: Less Potential for Toxicity Shown
By
Charles Bankhead
Radiation Therapy
,
Personalized Medicine
March 2013, Highlights
Ten-year disease control in patients with nonmetastatic breast cancer did not differ significantly between patients treated with a reduced-dose hypofractionated radiation therapy compared with a standard protocol, according to a study presented at the meeting.
Read Article
Intraoperative Radiotherapy Fares Well Against EBRT
By
Charles Bankhead
Radiation Therapy
,
Personalized Medicine
March 2013, Highlights
Low-dose intraoperative radiation therapy has proved comparable with whole-breast irradiation for preventing breast cancer recurrence, according to the preliminary results of the large randomized Targeted Intraoperative Radiotherapy (TARGIT-A) trial.
Read Article
Risk of Leukemia after Chemotherapy Small, but Real
By
Audrey Andrews
Chemotherapy
,
Personalized Medicine
March 2013, Highlights
Fewer than 0.5% of patients with breast cancer develop leukemia associated with chemotherapy, but this is 60% higher than the proportion documented in a previous analysis, according to a report based on the National Comprehensive Cancer Network (NCCN) database.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma